Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, NASH/ MASH treatment products, CKD ...
Morepen Laboratories reported revenue of 18.12 billion INR for fiscal year 2025, up 7.2% from fiscal year 2024, and net income of 1.18 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 4.84 billion INR, up 6.9% from a year before. India was its largest region in fiscal year 2025, with 61% of revenue. Its market capitalization was 70.04 billion INR as of October 12, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 12, 2026.
No profile data available.